SeaStar Medical Q1 net loss $12.7M, cash rises to $5M; Quelimmune launch imminent

SeaStar Medical Holding Corp

2024-Q1 EPS reported -$0.19

Net loss $12.7M ($0.19 per share) vs $7.1M ($0.54) in Q1 2023; no revenue recorded.
Cash and cash equivalents $5.0M as of March 31, 2024, up from $176K at Dec 31, 2023.
Quelimmune Pediatric received FDA approval in Feb 2024; initial sales expected in coming weeks at five children's hospitals.
NEUTRALIZE-AKI adult trial enrolled 31 subjects at eight sites; regulatory approval expected H2 2025.
January 2024 $9M at-the-market offering and appointment of David A. Green as CFO.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

SeaStar Medical Holding Corp reported financial results for the three months ended March 31, 2024.

Period: the three months ended March 31, 2024
Result: reported results

Exact text from the filing

On May 14, 2024, SeaStar Medical Holding Corporation (the “Company”) issued a press release announcing its financial condition and results of operations for the fiscal quarter-ended March 31, 2024.

View on SEC.gov

1047 earnings releases filed in the last 30 days. Browse all earnings releases →

SeaStar Medical Holding Corp filing history →

Source: SEC EDGAR

accession 0000950170-24-059518

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.